Signal detection is not one discipline but many, shaped by the scale and complexity of the organization practicing it. A small biotech monitoring a single asset and a global pharmaceutical company managing hundreds of products face the same regulatory expectations, yet they cannot meet them the same way. This white paper by Dr. Mohit Raizada maps how signal detection methodology evolves across small, mid-size, and large organizations, from qualitative, physician-led review to hybrid models and analytics-driven enterprise frameworks. It offers pharmacovigilance and drug safety leaders a practical, side-by-side comparison of data sources, statistical methods, governance structures, and technology, and it makes the case for matching methodology to organizational maturity rather than defaulting to a one-size-fits-all approach. Above all, it shows why expert medical judgment and a human-in-the-loop model remain the constants that keep safety decisions scientifically sound and regulator-trusted at every scale.

See where your organization sits on the maturity spectrum, and what fit-for-purpose signal detection looks like at your scale. Download the white paper to read the full analysis.